Table 1.
Densometric measurements of Western blot analyses
| Patient no. | AC
|
Patient no. | AD
|
||
|---|---|---|---|---|---|
| Control | βAP | Control | βAP | ||
| PKCα | |||||
| AG03652C | 1,238.8 + 35* | 121.1 + 23* | AG07872 | 507.3 + 102* | 532.9 + 78* |
| AG07310 | 1,031.1 + 208* | 145.3 + 41* | AG06263A | 468.2 | 399.7 |
| AG06241B | 880.5 + 103* | 267.5 + 94* | AG06848B | 584.5 | 451.5 |
| AG08044A | 1,340.3 + 211* | 214.1 + 71* | AG08563A | 656.5 + 38* | 534.1 + 103 |
| AG07141 | 1,141.3 + 301* | 466.7 + 107* | AG05770D | 880.8 | 799 |
| AG07603A | 1,472.3 + 251 | 330.6 + 122* | AG06838A | 664.2 | 603.2 |
| AG06842B | 813.7 + 219* | 243 + 100* | AG07377A | 575.1 | 337.8 |
| AG07665A | 1,143.9 + 291* | 312.2 + 101* | AG08527A | 682 | 538.2 |
| AG04560B | 1,871.2 + 437 | 420.1 + 122* | AG06840B | 153.9 | 117 |
| AG07867 | 778 + 283 | 194.7 + 18* | AG08170B | 660.8 | 573.9 |
| PKCγ | |||||
| AG03652C | 486.3 | 497.9 | AG07872 | 642.1 | 129.6 |
| AG07310 | 841.5 | 774.4 | AG06263A | 1,087.5 + 227* | 233.4 + 71* |
| AG06241B | 784.1 + 302* | 1,006.5 + 201* | AG06848B | 894.5 + 318* | 249.2 + 102* |
| AG08044A | 2,189.3 | 2,056.2 | AG08563A | 1,029.6 + 211* | 234.7 + 99* |
| AG07141 | 714.8 | 616.1 | AG05770D | 1,312.8 | 202.1 |
| AG07603A | 124.6 | 121 | AG06838A | 1,751.5 + 171* | 323.5 + 38* |
| AG06842B | 1,479.1 | 1,454.7 | AG07377A | 448.8 + 118* | 184.7 + 41 |
| AG07665A | 2,095.1 | 2,023.8 | AG08527A | 776.3 | 132.1 |
| AG04560B | 1,781.5 | 1,849.1 | AG06840B | 2,115.7 | 449.7 |
| AG07867 | 1,211 + 251* | 1,174 + 76 | AG08170B | 2,178 | 1,002.2 |
Values are the expression of the optical density of the immunoreactivity obtained from each single cell line. The Table shows the modifications in the immunoreactivity of PKCα or PKCγ from untreated and βAP(1-40)-treated fibroblasts from control (AC) or AD patients.
*
Results of the mean ± SEM of two or more experiments per group.